| Bioactivity | Tenapanor (AZD1722) is a potent and orally active sodium/hydrogen exchanger isoform 3 (NHE3) inhibitor. Tenapanor reduces intestinal phosphate absorption predominantly through reduction of passive paracellular phosphate flux. Tenapanor has the potential for the research of hyperphosphatemia[1][2]. | ||||||||||||
| Target | IC50: 5 nM (NHE3, human), 10 nM (NHE3, rat) | ||||||||||||
| In Vivo | Tenapanor (0.15, 0.5 mg/kg; p.o.) reduces passive paracellular phosphate absorption in rats[1].Tenapanor (0.15 mg/kg; p.o.; twice-daily for 11 consecutive days) increases the reduction in urinary phosphorus excretion in rats[2]. Animal Model: | ||||||||||||
| Name | Tenapanor | ||||||||||||
| CAS | 1234423-95-0 | ||||||||||||
| Formula | C50H66Cl4N8O10S2 | ||||||||||||
| Molar Mass | 1145.05 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. King AJ, et al. Inhibition of sodium/hydrogen exchanger 3 in the gastrointestinal tract by tenapanor reduces paracellular phosphate permeability. Sci Transl Med. 2018 Aug 29;10(456):eaam6474. [2]. King AJ, et al. Combination treatment with tenapanor and sevelamer synergistically reduces urinary phosphorus excretion in rats. Am J Physiol Renal Physiol. 2021 Jan 1;320(1):F133-F144. |
Tenapanor
CAS: 1234423-95-0 F: C50H66Cl4N8O10S2 W: 1145.05
Tenapanor (AZD1722) is a potent and orally active sodium/hydrogen exchanger isoform 3 (NHE3) inhibitor. Tenapanorreduces
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.